Illumina Building Clinical Momentum Amid Fading Competition, RBC Capital Markets Says

MT Newswires Live08-11 22:58

Illumina (ILMN) is building clinical momentum as competitive concerns surrounding the company are fading, RBC Capital Markets said in a note Monday.

The company's clinical sequencing revenue could grow at a durable mid-teens rate, driven by volume growth in oncology and easing pricing headwinds, according to the note.

RBC said that while customers are expected to evaluate competitive sequencing instruments, Illumina will likely retain its clinical market share.

Sequencing instrument sales could decline double digits in 2027 as they face more headwinds than previously expected, but clinical sequencing and sequencing services could offset this decline, the firm added.

RBC Capital Markets has an outperform rating and a $230 price target on the stock.

Price: 191.86, Change: +0.07, Percent Change: +0.04

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2658197479?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-11 22:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2658197479","market":"hk","top_or_hot":-1,"title":"Illumina Building Clinical Momentum Amid Fading Competition, RBC Capital Markets Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ILMN\">Illumina</a> (ILMN) is building clinical momentum as competitive concerns surrounding the company are fading, RBC Capital Markets said in a note Monday.</p><p>The company's clinical sequencing revenue could grow at a durable mid-teens rate, driven by volume growth in oncology and easing pricing headwinds, according to the note.</p><p>RBC said that while customers are expected to evaluate competitive sequencing instruments, Illumina will likely retain its clinical market share.</p><p>Sequencing instrument sales could decline double digits in 2027 as they face more headwinds than previously expected, but clinical sequencing and sequencing services could offset this decline, the firm added.</p><p>RBC Capital Markets has an outperform rating and a $230 price target on the stock.</p><p>Price: 191.86, Change: +0.07, Percent Change: +0.04</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Illumina Building Clinical Momentum Amid Fading Competition, RBC Capital Markets Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIllumina Building Clinical Momentum Amid Fading Competition, RBC Capital Markets Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-11 22:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ILMN\">Illumina</a> (ILMN) is building clinical momentum as competitive concerns surrounding the company are fading, RBC Capital Markets said in a note Monday.</p><p>The company's clinical sequencing revenue could grow at a durable mid-teens rate, driven by volume growth in oncology and easing pricing headwinds, according to the note.</p><p>RBC said that while customers are expected to evaluate competitive sequencing instruments, Illumina will likely retain its clinical market share.</p><p>Sequencing instrument sales could decline double digits in 2027 as they face more headwinds than previously expected, but clinical sequencing and sequencing services could offset this decline, the firm added.</p><p>RBC Capital Markets has an outperform rating and a $230 price target on the stock.</p><p>Price: 191.86, Change: +0.07, Percent Change: +0.04</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0708994859.HKD","symbol_name":"TEMPLETON GLOBAL \"A\" (HKD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2658197479","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2658197479","pubTimestamp":1786460297,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Illumina  is building clinical momentum as competitive concerns surrounding the company are fading, RBC Capital Markets said in a note Monday.The company's clinical sequencing revenue could grow at a durable mid-teens rate, driven by volume growth in oncology and easing pricing headwinds, according to the note.RBC said that while customers are expected to evaluate competitive sequencing instruments, Illumina will likely retain its clinical market share.Sequencing instrument sales could decline double digits in 2027 as they face more headwinds than previously expected, but clinical sequencing and sequencing services could offset this decline, the firm added.RBC Capital Markets has an outperform rating and a $230 price target on the stock.Price: 191.86, Change: +0.07, Percent Change: +0.04","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","GSIB":"THEMES GLOBAL SYSTEMICALLY IMPORTANT BANKS ETF","BK4588":"碎股","BK4534":"瑞士信贷持仓","GNOM":"Global X Genomics & Biotechnology ETF","ILMN":"Illumina","BK4585":"ETF&股票定投概念","BK4548":"巴美列捷福持仓","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","GNMX":"Corgi Genomics & Precision Medicine ETF","BK4535":"淡马锡持仓","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","BK4121":"生命科学工具和服务","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","BK4207":"综合性银行"},"translate_title":"加拿大皇家银行资本市场表示，Illumina 在竞争减弱的情况下建立临床势头","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GNMX":0.6,"GSIB":0.6,"GNOM":0.6,"ILMN":1.5},"content_text":"Illumina (ILMN) is building clinical momentum as competitive concerns surrounding the company are fading, RBC Capital Markets said in a note Monday.The company's clinical sequencing revenue could grow at a durable mid-teens rate, driven by volume growth in oncology and easing pricing headwinds, according to the note.RBC said that while customers are expected to evaluate competitive sequencing instruments, Illumina will likely retain its clinical market share.Sequencing instrument sales could decline double digits in 2027 as they face more headwinds than previously expected, but clinical sequencing and sequencing services could offset this decline, the firm added.RBC Capital Markets has an outperform rating and a $230 price target on the stock.Price: 191.86, Change: +0.07, Percent Change: +0.04","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2658197479","isCrawlerRequest":true}